Targeting PRAS40: a novel therapeutic strategy for human diseases

References

• Kovacina KS, Park GY, Bae SS, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278(12):10189–10194.
   PubMed Web of Science ®Google Scholar
• Beausoleil SA, Jedrychowski M, Schwartz D, et al. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA. 2004;101(33):12130–12135.
   PubMed Web of Science ®Google Scholar
• Wiza C, Nascimento EB, Ouwens DM. Role of PRAS40 in Akt and mTOR signaling in health and disease. Am J Physiol Endocrinol Metab. 2012;302(12):E1453–1460.
   PubMed Web of Science ®Google Scholar
• Macias MJ, Wiesner S, Sudol M. WW and SH3 domains, two different scaffolds to recognize proline-rich ligands. FEBS Lett. 2002;513(1):30–37.
   PubMed Web of Science ®Google Scholar
• Nascimento EB, Ouwens DM. PRAS40: target or modulator of mTORC1 signalling and insulin action? Arch Physiol Biochem. 2009;115(4):163–175.
   PubMedGoogle Scholar
• Xiao X, Liu J, Hu J, et al. Protective effect of protopine on the focal cerebral ischaemic injury in rats. Basic Clin Pharmacol Toxicol. 2007;101(2):85–89.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Q, Wen Q, et al. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal. 2012;24(1):17–24.
   PubMed Web of Science ®Google Scholar
• Wang L, Harris TE, Lawrence JC. Jr.: Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem. 2008;283(23):15619–15627.
   PubMed Web of Science ®Google Scholar
• Nascimento EB, Snel M, Guigas B, et al. Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cell Signal. 2010;22(6):961–967.
   PubMed Web of Science ®Google Scholar
• Chong ZZ. Targeting PRAS40 for multiple diseases. Drug Discov Today. 2016;21(8):1222–1231.
   PubMed Web of Science ®Google Scholar
• Oshiro N, Takahashi R, Yoshino K, et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem. 2007;282(28):20329–20339.
   PubMed Web of Science ®Google Scholar
• Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332(6035):1317–1322.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Q, Zhang L, et al. Insulin-like growth factor-1 induces the phosphorylation of PRAS40 via the PI3K/Akt signaling pathway in PC12 cells. Neurosci Lett. 2012;516(1):105–109.
   PubMed Web of Science ®Google Scholar
• Lu Y, Li L, Wu G, et al. Effect of PI3K/Akt signaling pathway on PRAS40Thr246 phosphorylation in gastric cancer cells. Iran J Public Health. 2019;48(12):2196–2204.
   PubMed Web of Science ®Google Scholar
• Hou G, Zhao Q, Zhang M, et al. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma. Biomed Pharmacother. 2018;106:1348–1356.
   PubMed Web of Science ®Google Scholar
• Thedieck K, Polak P, Kim ML, et al. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One. 2007;2(11):e1217.
   PubMed Web of Science ®Google Scholar
• Toschi A, Lee E, Xu L, et al. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009;29(6):1411–1420.
   PubMed Web of Science ®Google Scholar
• Hao J, Li F, Liu W, et al. Phosphorylation of PRAS40-Thr246 involved in renal lipid accumulation of diabetes. J Cell Physiol. 2014;229(8):1069–1077.
   PubMed Web of Science ®Google Scholar
• Nascimento EB, Fodor M, van der Zon GC, et al. Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes. 2006;55(12):3221–3228.
   PubMed Web of Science ®Google Scholar
• Frey JW, Jacobs BL, Goodman CA, et al. A role for Raptor phosphorylation in the mechanical activation of mTOR signaling. Cell Signal. 2014;26(2):313–322.
   PubMed Web of Science ®Google Scholar
• Kaur H, Moreau R. Curcumin represses mTORC1 signaling in Caco-2 cells by a two-sided mechanism involving the loss of IRS-1 and activation of AMPK. Cell Signal. 2021;78:109842.
   PubMed Web of Science ®Google Scholar
• Kearney AL, Cooke KC, Norris DM, et al. Serine 474 phosphorylation is essential for maximal Akt2 kinase activity in adipocytes. J Biol Chem. 2019;294(45):16729–16739.
   PubMed Web of Science ®Google Scholar
• Subbannayya T, Leal-Rojas P, Zhavoronkov A, et al. PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40)). J Cell Commun Signal. 2019;13(2):163–177.
   PubMed Web of Science ®Google Scholar
• Fonseca BD, Smith EM, Lee VH, et al. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem. 2007;282(34):24514–24524.
   PubMed Web of Science ®Google Scholar
• Vander Haar E, Lee SI, Bandhakavi S, et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9(3):316–323.
   PubMed Web of Science ®Google Scholar
• Al Fayi M, Otifi H, Alshyarba M, et al. Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling. J Drug Target. 2020;28(9):913–922.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xiao L, Fu W, et al. Gaudichaudione H inhibits inflammatory responses in macrophages and dextran sodium sulfate-induced colitis in mice. Front Pharmacol. 2019;10:1561.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Wang S, et al. PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS One. 2012;7(9):e45456.
   PubMed Web of Science ®Google Scholar
• Chen K, Xu H, Zhao J. Bloom syndrome protein activates AKT and PRAS40 in prostate cancer cells. Oxid Med Cell Longev. 2019;2019:3685817.
   PubMed Web of Science ®Google Scholar
• Zhao W, Chen S, Hou X, et al. CHK2 promotes anoikis and is associated with the progression of papillary thyroid cancer. Cell Physiol Biochem. 2018;45(4):1590–1602.
   PubMedGoogle Scholar
• Yang W, Yang LF, Song ZQ, et al. PRAS40 alleviates neurotoxic prion peptide-induced apoptosis via mTOR-AKT signaling. CNS Neurosci Ther. 2017;23(5):416–427.
   PubMed Web of Science ®Google Scholar
• Dougherty MI, Lehman CE, Spencer A, et al. PRAS40 phosphorylation correlates with insulin-like growth factor-1 receptor-induced resistance to epidermal growth factor receptor inhibition in head and neck cancer cells. Mol Cancer Res. 2020;18(9):1392–1401.
   PubMed Web of Science ®Google Scholar
• Wu MY, Yiang GT, Liao WT, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 2018;46(4):1650–1667.
   PubMedGoogle Scholar
• Shin MJ, Kim DW, Jo HS, et al. Tat-PRAS40 prevent hippocampal HT-22 cell death and oxidative stress induced animal brain ischemic insults. Free Radic Biol Med. 2016;97:250–262.
   PubMed Web of Science ®Google Scholar
• Volkers M, Konstandin MH, Doroudgar S, et al. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Circulation. 2013;128(19):2132–2144.
   PubMed Web of Science ®Google Scholar
• Guo J, Jayaprakash P, Dan J, et al. PRAS40 connects microenvironmental stress signaling to exosome-mediated secretion. Mol Cell Biol. 2017;37(19):e00171-17.
   PubMed Web of Science ®Google Scholar
• Niu Q, Zhao W, Wang J, et al. LicA induces autophagy through ULK1/Atg13 and ROS pathway in human hepatocellular carcinoma cells. Int J Mol Med. 2018;41(5):2601–2608.
   PubMed Web of Science ®Google Scholar
• Duan J, Du J, Jin R, et al. Iron oxide nanoparticles promote vascular endothelial cells survival from oxidative stress by enhancement of autophagy. Regen Biomater. 2019;6(4):221–229.
   PubMed Web of Science ®Google Scholar
• Pozuelo-Rubio M. 14-3-3 proteins are regulators of autophagy. Cells. 2012;1(4):754–773.
   PubMedGoogle Scholar
• Kazi AA, Lang CH. PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts. Mol Med. 2010;16(9–10):359–371.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang X, Guo H, et al. PTEN inhibitor VO-OHpic suppresses TSC2-/- MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway. Exp Ther Med. 2020;19(6):3565–3570.
   PubMed Web of Science ®Google Scholar
• Gozuacik D, Akkoc Y, Ozturk DG, et al. Autophagy-regulating microRNAs and cancer. Front Oncol. 2017;7:65.
   PubMed Web of Science ®Google Scholar
• Xie Y, Chen L, Zhou J, et al. TGFbeta signaling-induced miRNA participates in autophagic regulation by targeting PRAS40 in mesenchymal subtype of glioblastoma. Cancer Biol Med. 2020;17(3):664–675.
   PubMed Web of Science ®Google Scholar
• Cai S, Yang Q, Cao Y, et al. PF4 antagonizes retinal neovascularization via inhibiting PRAS40 phosphorylation in a mouse model of oxygen-induced retinopathy. Biochim Biophys Acta Mol Basis Dis. 2020;1866(3):165604.
   PubMed Web of Science ®Google Scholar
• Mabeta P. PF573,228 inhibits vascular tumor cell growth, migration as well as angiogenesis, induces apoptosis and abrogates PRAS40 and S6RP phosphorylation. Acta Pharm. 2016;66(3):399–410.
   PubMed Web of Science ®Google Scholar
• Zanini S, Renzi S, Giovinazzo F, et al. mTOR pathway in gastroenteropancreatic neuroendocrine tumor (GEP-NETs). Front Endocrinol (Lausanne). 2020;11:562505.
   PubMed Web of Science ®Google Scholar
• Qi S, Li C, Kong X, et al. Dexmedetomidine suppresses oxidative stress and inflammation of nucleus pulposus cells by activating the PI3K/Akt signaling pathway. Pharmazie. 2020;75(10):505–509.
   PubMed Web of Science ®Google Scholar
• Xu F, Na L, Li Y, et al. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2020;10:54.
   PubMed Web of Science ®Google Scholar
• Dera AA, Rajagopalan P, Alfhili MA, Ahmed I, et al. Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid-induced hyperuricemia rats. Biofactors. 2020;46(2):292–300.
   PubMed Web of Science ®Google Scholar
• Dera A, Rajagopalan P. Thymoquinone attenuates phosphorylation of AKT to inhibit kidney cancer cell proliferation. J Food Biochem. 2019;43(4):e12793.
   PubMed Web of Science ®Google Scholar
• Volkers M, Toko H, Doroudgar S, et al. Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1. Proc Natl Acad Sci U S A. 2013;110(31):12661–12666.
   PubMed Web of Science ®Google Scholar
• Cho H, Thorvaldsen JL, Chu Q, et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001;276(42):38349–38352.
   PubMed Web of Science ®Google Scholar
• Cho H, Mu J, Kim JK, Thorvaldsen JL, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001;292(5522):1728–1731.
   PubMed Web of Science ®Google Scholar
• Andersen JN, Sathyanarayanan S, Di Bacco A, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010;2(43):43ra55.
   PubMed Web of Science ®Google Scholar
• Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 2015;25(9):545–555.
   PubMed Web of Science ®Google Scholar
• Yun YS, Kim KH, Tschida B, et al. mTORC1 coordinates protein synthesis and immunoproteasome formation via PRAS40 to prevent accumulation of protein stress. Mol Cell. 2016;61(4):625–639.
   PubMed Web of Science ®Google Scholar
• Aylett CH, Sauer E, Imseng S, et al. Architecture of human mTOR complex 1. Science. 2016;351(6268):48–52.
   PubMed Web of Science ®Google Scholar
• Gordon BS, Kazi AA, Coleman CS, et al. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells. Cell Signal. 2014;26(3):461–467.
   PubMed Web of Science ®Google Scholar
• Lin J, Fang Y, Zhang M, et al. Phosphorylation of PRAS40 contributes to the activation of the PI3K/AKT/mTOR signaling pathway and the inhibition of autophagy following status epilepticus in rats. Exp Ther Med. 2020;20(4):3625–3632.
   PubMed Web of Science ®Google Scholar
• Zhang KS, Schecker J, Krull A, et al. PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cells. Sci Rep. 2019;9(1):16787.
   PubMedGoogle Scholar
• Xu Q, Wu N, Li X, et al. Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway. Cell Death Dis. 2019;10(12):874.
   PubMedGoogle Scholar
• Hong-Brown LQ, Brown CR, Kazi AA, et al. Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interaction. J Cell Biochem. 2010;109(6):1172–1184.
   PubMed Web of Science ®Google Scholar
• Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25(6):903–915.
   PubMed Web of Science ®Google Scholar
• Maity S, Das F, Kasinath BS, et al. TGFβ acts through PDGFRβ to activate mTORC1 via the Akt/PRAS40 axis and causes glomerular mesangial cell hypertrophy and matrix protein expression. J Biol Chem. 2020;295(42):14262–14278.
   PubMed Web of Science ®Google Scholar
• Fonseca BD, Lee VH, Proud CG. The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK. Biochem J. 2008;411(1):141–149.
   PubMedGoogle Scholar
• Pallares-Cartes C, Cakan-Akdogan G, Teleman AA. Tissue-specific coupling between insulin/IGF and TORC1 signaling via PRAS40 in Drosophila. Dev Cell. 2012;22(1):172–182.
   PubMed Web of Science ®Google Scholar
• Zhu G, Qi Q, Havel JJ, et al. PRAS40 promotes NF-κB transcriptional activity through association with p65. Oncogenesis. 2017;6(9):e381.
   PubMedGoogle Scholar
• Zhang F, Beharry ZM, Harris TE, et al. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009;8(9):846–853.
   PubMed Web of Science ®Google Scholar
• Velazquez R, Shaw DM, Caccamo A, et al. Pim1 inhibition as a novel therapeutic strategy for Alzheimer's disease. Mol Neurodegener. 2016;11(1):52.
   PubMedGoogle Scholar
• Li YH, Li XF, Liu JT, et al. PKM2, a potential target for regulating cancer. Gene. 2018;668:48–53.
   PubMed Web of Science ®Google Scholar
• Magadum A, Singh N, Kurian AA, et al. PKM2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration. Circulation. 2020;141(15):1249–1265.
   PubMed Web of Science ®Google Scholar
• Dey P, Kundu A, Sachan R, et al. PKM2 knockdown induces autophagic cell death via AKT/mTOR pathway in human prostate cancer cells. Cell Physiol Biochem. 2019;52(6):1535–1552.
   PubMedGoogle Scholar
• He CL, Bian YY, Xue Y, et al. Pyruvate kinase M2 activates mTORC1 by phosphorylating AKT1S1. Sci Rep. 2016;6:21524.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang YR, Chen J, et al. Pterostilbene attenuates experimental atherosclerosis through restoring catalase-mediated redox balance in vascular smooth muscle cells. J Agric Food Chem. 2019;67(46):12752–12760.
   PubMed Web of Science ®Google Scholar
• Jin JK, Blackwood EA, Azizi K, et al. ATF6 decreases myocardial ischemia/reperfusion damage and links ER stress and oxidative stress signaling pathways in the heart. Circ Res. 2017;120(5):862–875.
   PubMed Web of Science ®Google Scholar
• Xiong X, Xie R, Zhang H, et al. PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways. Neurobiol Dis. 2014;66:43–52.
   PubMed Web of Science ®Google Scholar
• Gao X, Yang H, Su J, et al. Aescin protects neuron from ischemia-reperfusion injury via regulating the PRAS40/mTOR signaling pathway. Oxid Med Cell Longev. 2020;2020:7815325.
   PubMed Web of Science ®Google Scholar
• Lv D, Guo L, Zhang T, et al. PRAS40 signaling in tumor. Oncotarget. 2017;8(40):69076–69085.
   PubMedGoogle Scholar
• Yao L, Xuan Y, Zhang H, et al. Reciprocal REGgamma-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma. Oncogene. 2021;40(3):677–692.
   PubMed Web of Science ®Google Scholar
• Ganapathy K, Staklinski S, Hasan MF, et al. Multifaceted function of microRNA-299-3p fosters an antitumor environment through modulation of androgen receptor and VEGFA signaling pathways in prostate cancer. Sci Rep. 2020;10(1):5167.
   PubMed Web of Science ®Google Scholar
• Chen H, Yang J, Hao J, et al. A novel flavonoid kushenol Z from Sophora flavescens mediates mTOR pathway by inhibiting phosphodiesterase and Akt activity to induce apoptosis in non-small-cell lung cancer cells. Molecules. 2019;24(24):4425.
   Web of Science ®Google Scholar
• Mi W, Ye Q, Liu S, et al. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Oncotarget. 2015;6(16):13962–13977.
   PubMed Web of Science ®Google Scholar
• Lu YZ, Deng AM, Li LH, et al. Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer. Arch Med Sci. 2014;10(1):149–153.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Deng X, Liu Y, et al. Correction to: PKM2, function and expression and regulation. Cell Biosci. 2019;9:59.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wei P, Lv W, et al. MELK is upregulated in advanced clear cell renal cell carcinoma and promotes disease progression by phosphorylating PRAS40. Cell Transplant. 2019;28(1_suppl):37S–50S.
   PubMed Web of Science ®Google Scholar
• Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell. 2013;153(3):516–519.
   PubMed Web of Science ®Google Scholar
• Jiang D, Cho WC, Li Z, et al. MiR-758-3p suppresses proliferation, migration and invasion of hepatocellular carcinoma cells via targeting MDM2 and mTOR. Biomed Pharmacother. 2017;96:535–544.
   PubMed Web of Science ®Google Scholar
• Qi Z, Zhang T, Song L, et al. PRAS40 hyperexpression promotes hepatocarcinogenesis. EBioMedicine. 2020;51:102604.
   PubMed Web of Science ®Google Scholar
• Das F, Dey N, Bera A, et al. MicroRNA-214 reduces insulin-like growth factor-1 (IGF-1) receptor expression and downstream mTORC1 signaling in renal carcinoma cells. J Biol Chem. 2016;291(28):14662–14676.
   PubMed Web of Science ®Google Scholar
• Kassai H, Sugaya Y, Noda S, et al. Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases. Cell Rep. 2014;7(5):1626–1639.
   PubMed Web of Science ®Google Scholar
• Maiese K. Driving neural regeneration through the mammalian target of rapamycin. Neural Regen Res. 2014;9(15):1413–1417.
   PubMed Web of Science ®Google Scholar
• Shang YC, Chong ZZ, Wang S, et al. Wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern β-amyloid apoptotic injury of microglia. Curr Neurovasc Res. 2012;9(4):239–249.
   PubMed Web of Science ®Google Scholar
• Park JH, Shin BN, Ahn JH, et al. Ischemia-induced changes of PRAS40 and p-PRAS40 immunoreactivities in the gerbil hippocampal CA1 region after transient cerebral ischemia. Cell Mol Neurobiol. 2016;36(5):821–828.
   PubMed Web of Science ®Google Scholar
• Wiza C, Herzfeld de Wiza D, Nascimento EB, et al. Knockdown of PRAS40 inhibits insulin action via proteasome-mediated degradation of IRS1 in primary human skeletal muscle cells. Diabetologia. 2013;56(5):1118–1128.
   PubMed Web of Science ®Google Scholar
• Das F, Ghosh-Choudhury N, Mariappan MM, et al. Hydrophobic motif site-phosphorylated protein kinase CβII between mTORC2 and Akt regulates high glucose-induced mesangial cell hypertrophy. Am J Physiol Cell Physiol. 2016;310(7):C583–596.
   PubMed Web of Science ®Google Scholar
• Dey N, Ghosh-Choudhury N, Das F, et al. Ghosh Choudhury G: PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy. J Cell Physiol. 2010;225(1):27–41.
   PubMed Web of Science ®Google Scholar
• Volkers M, Doroudgar S, Nguyen N, et al. PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity. EMBO Mol Med. 2014;6(1):57–65.
   PubMed Web of Science ®Google Scholar
• Zhao S, Li B, Li C, et al. The apoptosis regulator 14-3-3eta and its potential as a therapeutic target in pituitary oncocytoma. Front Endocrinol (Lausanne). 2019;10:797.
   PubMed Web of Science ®Google Scholar
• Sun D, Luo T, Dong P, et al. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma. J Cell Biochem. 2020;121(4):2828–2838.
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35.
   PubMed Web of Science ®Google Scholar
• Chong ZZ. mTOR: a novel therapeutic target for diseases of multiple systems. Curr Drug Targets. 2015;16(10):1107–1132.
   PubMed Web of Science ®Google Scholar
• Dera AA, Rajagopalan P, Al Fayi M, et al. Indirubin-3-monoxime and thymoquinone exhibit synergistic efficacy as therapeutic combination in in-vitro and in-vivo models of Lung cancer. Arch Pharm Res. 2020;43(6):655–665.
   PubMed Web of Science ®Google Scholar